Advertisement
Canada markets close in 3 hours 58 minutes

  • S&P/TSX

    21,814.44
    -59.28 (-0.27%)
     

  • S&P 500

    5,018.15
    -53.48 (-1.05%)
     

  • DOW

    37,912.40
    -548.52 (-1.43%)
     

  • CAD/USD

    0.7303
    +0.0005 (+0.07%)
     

  • CRUDE OIL

    82.46
    -0.35 (-0.42%)
     

  • Bitcoin CAD

    87,786.91
    -656.67 (-0.74%)
     

  • CMC Crypto 200

    1,381.84
    -0.73 (-0.05%)
     

  • GOLD FUTURES

    2,342.80
    +4.40 (+0.19%)
     

  • RUSSELL 2000

    1,966.40
    -29.02 (-1.45%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,481.69
    -231.06 (-1.47%)
     

  • VOLATILITY

    16.72
    +0.75 (+4.69%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6811
    -0.0008 (-0.12%)
     
MARKETS LIVE BLOG:

STOCKS SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

ImmuPharma expects new Lupozor study to begin in H2 2023

News Direct
·1 min read

London, UK --News Direct-- ImmuPharma PLC

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) chief executive Tim McCarthy spoke to Thomas Warner at Proactive's London studio after announcing that its partner Avion Pharmaceuticals is to launch an adaptive phase II/III clinical study on Lupuzor, the former’s discovery and putative treatment for systemic lupus erythematosus (SLE). McCarthy reveals the reasons for choosing the particular type of study and explains what else investors can expect from ImmuPharma during 2023.

Proactive UK Finance News

Contact Details

Proactive UK Ltd

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immupharma-expects-new-lupozor-study-to-begin-in-h2-2023-408143897